NO20025739L - Forbindelser med en sulfonamidgruppe og farmasöytiske preparater som inneholder disse forbindelsene - Google Patents

Forbindelser med en sulfonamidgruppe og farmasöytiske preparater som inneholder disse forbindelsene

Info

Publication number
NO20025739L
NO20025739L NO20025739A NO20025739A NO20025739L NO 20025739 L NO20025739 L NO 20025739L NO 20025739 A NO20025739 A NO 20025739A NO 20025739 A NO20025739 A NO 20025739A NO 20025739 L NO20025739 L NO 20025739L
Authority
NO
Norway
Prior art keywords
compounds
group
erythrocytes
substances
active agent
Prior art date
Application number
NO20025739A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025739D0 (no
Inventor
Walter Elger
Alexander Hillisch
Annemarie Hedden
Sigfrid Schwarz
Klaus Schoellkopf
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7644802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20025739(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20025739L publication Critical patent/NO20025739L/no
Publication of NO20025739D0 publication Critical patent/NO20025739D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
NO20025739A 2000-05-31 2002-11-29 Forbindelser med en sulfonamidgruppe og farmasöytiske preparater som inneholder disse forbindelsene NO20025739D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10027887A DE10027887A1 (de) 2000-05-31 2000-05-31 Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
PCT/EP2001/005169 WO2001091797A2 (de) 2000-05-31 2001-05-08 Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Publications (2)

Publication Number Publication Date
NO20025739L true NO20025739L (no) 2002-11-29
NO20025739D0 NO20025739D0 (no) 2002-11-29

Family

ID=7644802

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025739A NO20025739D0 (no) 2000-05-31 2002-11-29 Forbindelser med en sulfonamidgruppe og farmasöytiske preparater som inneholder disse forbindelsene

Country Status (29)

Country Link
US (2) US7507725B2 (he)
EP (1) EP1294402B2 (he)
JP (1) JP2003534386A (he)
KR (3) KR20030017524A (he)
CN (1) CN1441678A (he)
AT (1) ATE315407T1 (he)
AU (2) AU6593301A (he)
BG (1) BG107556A (he)
BR (1) BR0111294A (he)
CA (1) CA2410630A1 (he)
CZ (1) CZ2003621A3 (he)
DE (2) DE10027887A1 (he)
DK (1) DK1294402T4 (he)
EA (1) EA006432B1 (he)
ES (1) ES2256256T5 (he)
HR (1) HRP20021038B1 (he)
HU (1) HUP0301949A3 (he)
IL (2) IL152932A0 (he)
ME (1) MEP14608A (he)
MX (1) MXPA02011844A (he)
NO (1) NO20025739D0 (he)
NZ (1) NZ535201A (he)
PL (1) PL206462B1 (he)
PT (1) PT1294402E (he)
SK (1) SK2912003A3 (he)
UA (1) UA76953C2 (he)
WO (1) WO2001091797A2 (he)
YU (1) YU90102A (he)
ZA (1) ZA200209490B (he)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
DE102004025986A1 (de) * 2004-05-21 2005-12-15 Schering Ag Steroid-Prodrugs mit androgener Wirkung
US20050282793A1 (en) * 2004-05-21 2005-12-22 Ralf Wyrwa Steroid prodrugs with androgenic action
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
DE102005057225A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057224A1 (de) 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
DE102005057408A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Sulfamoylsulfonat-Prodrugs
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
DE102005057421A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Heteroaromatische Sulfonamid-Prodrugs
US8777182B2 (en) 2008-05-20 2014-07-15 Grinon Industries Fluid transfer assembly and methods of fluid transfer
JP5415527B2 (ja) 2008-05-20 2014-02-12 グリノン・インダストリーズ 流体移送アセンブリおよび流体移送方法
US9100458B2 (en) * 2008-09-11 2015-08-04 At&T Intellectual Property I, L.P. Apparatus and method for delivering media content
CN101987102A (zh) * 2009-08-05 2011-03-23 天津金耀集团有限公司 一种糖皮质激素杂芳香基氨磺酰基羧酸酯的眼用抗炎组合物
CN101987104A (zh) * 2009-08-05 2011-03-23 天津金耀集团有限公司 一种杂芳香基氨磺酰基羧酸酯碳酸酐酶抑制剂的眼用组合物
RU2612985C2 (ru) * 2011-12-30 2017-03-14 Гринон Индастриз Узел переноса текучей среды и способы переноса текучей среды
AU2014287049B2 (en) 2013-07-11 2019-09-26 Evestra, Inc. Pro-drug forming compounds
EP3173113A1 (en) * 2015-11-27 2017-05-31 Sanofi-Aventis Deutschland GmbH An injection needle assembly
CN108601901B (zh) 2015-11-27 2021-02-26 赛诺菲-安万特德国有限公司 具有帽的药物输送装置
EP3697421B1 (en) 2017-10-19 2024-04-17 Evestra, Inc. Longer-acting progestin prodrug contraceptives

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1203042B (de) * 1963-11-21 1965-10-14 Schering Ag Fungizide Mittel
GB1593609A (en) 1978-01-31 1981-07-22 Christiaens Sa A Pyridine sulfonamides
US4244940A (en) * 1978-09-05 1981-01-13 Bio-Rad Laboratories, Inc. Single-incubation two-site immunoassay
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5001234A (en) 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5116828A (en) 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5025031A (en) 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
GB9118478D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
US5571933A (en) 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
DE19540233B4 (de) * 1995-10-19 2005-08-25 Schering Ag Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5705495A (en) * 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
DE19712488A1 (de) † 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
WO2000006475A1 (en) 1998-07-29 2000-02-10 Crisplant A/S Parcel singulation system
US6583130B1 (en) 1999-09-13 2003-06-24 Schering Ag C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceutical compositions containing these compounds
US6958327B1 (en) * 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
KR20020087930A (ko) * 2000-01-14 2002-11-23 스테릭스 리미티드 조성물
US7378404B2 (en) 2000-04-12 2008-05-27 Schering Aktiengesellschaft 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
WO2002079146A2 (en) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US20020156068A1 (en) * 2001-03-22 2002-10-24 Behan Dominic P. Anti-psychosis combination
US6956031B2 (en) 2002-03-27 2005-10-18 Schering Aktiengesellschaft 11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
DE10226326A1 (de) 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
WO2005051401A2 (en) 2003-11-26 2005-06-09 Schering Aktiengesellschaft Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
DE102004025985A1 (de) 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
DE102004025986A1 (de) 2004-05-21 2005-12-15 Schering Ag Steroid-Prodrugs mit androgener Wirkung
US20050277625A1 (en) 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
DE102004025966A1 (de) 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450

Also Published As

Publication number Publication date
PT1294402E (pt) 2006-05-31
HUP0301949A2 (hu) 2003-09-29
KR20090090398A (ko) 2009-08-25
US20040014781A1 (en) 2004-01-22
UA76953C2 (en) 2006-10-16
EP1294402A2 (de) 2003-03-26
IL152932A (he) 2007-07-04
CZ2003621A3 (cs) 2003-12-17
EA006432B1 (ru) 2005-12-29
ES2256256T3 (es) 2006-07-16
WO2001091797A2 (de) 2001-12-06
EP1294402B2 (de) 2009-08-12
CN1441678A (zh) 2003-09-10
BG107556A (bg) 2004-01-30
AU6593301A (en) 2001-12-11
PL206462B1 (pl) 2010-08-31
DE10027887A1 (de) 2001-12-13
IL152932A0 (en) 2003-06-24
CA2410630A1 (en) 2002-11-28
DK1294402T4 (da) 2009-11-23
MXPA02011844A (es) 2004-05-17
EP1294402B1 (de) 2006-01-11
BR0111294A (pt) 2003-06-10
ZA200209490B (en) 2005-03-10
JP2003534386A (ja) 2003-11-18
ES2256256T5 (es) 2009-12-11
AU2001265933B2 (en) 2007-10-18
NO20025739D0 (no) 2002-11-29
NZ535201A (en) 2007-01-26
YU90102A (sh) 2006-05-25
US20090023896A1 (en) 2009-01-22
US7507725B2 (en) 2009-03-24
WO2001091797A3 (de) 2002-06-20
MEP14608A (en) 2010-06-10
DK1294402T3 (da) 2006-05-22
HUP0301949A3 (en) 2010-01-28
HRP20021038B1 (en) 2008-08-31
ATE315407T1 (de) 2006-02-15
KR20080038460A (ko) 2008-05-06
SK2912003A3 (en) 2003-09-11
KR20030017524A (ko) 2003-03-03
DE50108674D1 (de) 2006-04-06
EA200201201A1 (ru) 2003-06-26
HRP20021038A2 (en) 2004-10-31
PL361426A1 (en) 2004-10-04

Similar Documents

Publication Publication Date Title
NO20025739D0 (no) Forbindelser med en sulfonamidgruppe og farmasöytiske preparater som inneholder disse forbindelsene
TR200402656T4 (tr) Antikanser ajanları olarak faydalı tiyofen türevleri
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
DK1140918T3 (da) Thrombininhibitorer
PT928788E (pt) Compostos farmaceuticamente activos
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
BR0010938A (pt) Derivados da 13-metil eritromicina
ATE305473T1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
SE0102055D0 (sv) New Compounds
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
DE69828522D1 (de) Antithrombotische mittel
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
BR0109573A (pt) Composto ou uma pró-droga ou um sal farmacologicamente aceitável do mesmo, agente, composição farmacêutica, e, uso de um composto ou uma pró-droga ou um sal farmacologicamente aceitável do mesmo
EA200400382A1 (ru) Применение специфической дозы фондапаринукса натрия для лечения окс
BRPI0411043A (pt) composição medicinal
ATE231838T1 (de) N,n'-diacylthiocystine
GT199700137A (es) Nuevas composiciones farmaceuticas que contienen como principio activo a derivados de n-sulfonil indolina.
HUP0000552A2 (hu) Egy O-(3-piperidino-2hidroxi-1-propil)-hidroximsav halogenidszármazék, annak alkalmazása, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
FR2833945A1 (fr) N-cyclopropylmethyl-azacycloalcanes, compositions les contenant et procedes de preparation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application